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LOBENZARIT disodtulIl (CCA) is a novel immunomo-
dulatory drug useful in the treatment of chronic
inflammations. Its principal mechanism of action
seems to be through enhancing the T suppressor/
T helper lymphocyte ratio. However, the mole-
cular basis for these actions remains unclear. In
this study it was found that CCA inhibits the pro-
duction of guanosine 3’,5’-cyclic monophosphate
almost completely when present in concentra-
tions of lmM. Further results demonstrated that
such inhibition could also be explained by inter-
ference in constitutive nitric oxide generation. In
addition to previous f’mdings, more insight into
the molecular mechanism of action of CCA is
provided.
Key words: Anti-inflammatory action, cGMP, Chronic
inflammation, Immunomodulator, Lobenzarit disodium,
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Introduction
N-(2-carboxyl phenyl)-4-chloro anthranilic acid
disodium salt (CCA), known as lobenzarit dis-
odium, is a novel immunomodulatory drug
useless in the treatment of acute inflammation
but experimentally very useful in the treatment of
chronic inflammatory auto-immune diseases such
as rheumatoid arthritis
2 and diabetes.3 Its
mechanism of action may be related to its capa-
city to enhance the T suppressor/T helper lym-
phocyte ratio.4 However, from a molecular point
of view the nature of the effect remains unclear.
CCA is a radical scavenging molecule derived
from anthranilic acid5 which as far as is known
shares structural features with known inhibitors
of the guanylate cyclase pathway, such as chlor-
promazine and methylene blue. Considering the
crucial role of cyclic nucleotides in many of the
activation processes of the immune system
6 we
decided to investigate the possible effect of CCA
upon the generation of guanosine Y,5’-cyclic
monophosphate (cGMP) and the closely related
nitric oxide (NO) metabolic pathway.
Two major nitric oxide synthases (NOS) have
been reported: the inducible pathway (iNOS),
that is mainly dependent on inflammatory
stimuli,
7 and the constitutive pathway (cNOS),
that is controlled by calmodulin and cytosolic
calcium levels.’9 Both enzymes are used by t-
arginine in the presence of molecular oxygen to
0 produce t-citrulline and NO, although the dis-
tinguishable kinetic effects of the cNOS
1 enable
it to mediate in the generation of cGMP.9
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cGMP, in particular, is known to be respon-
sible for many immune inflammatory processes
including macrophage activation,
12 lymphocyte
ascular proliferation, v smooth muscle relaxa-
tion,
14 mast cell degranulation,
15 chemotaxis16
17 and platelet aggregation, and adhesion to endo-
thelium.
8 Therefore we investigated the effect of
CCA upon the constitutive NO-cGMP metabolic
pathways, in order to gain more insight into the
pharmacodynamics of CCA, which might explain
its therapeutic proficiency in the treatment of
chronic inflammatory diseases.
Materials and Methods
Chemicals: CCA was synthesized by Dr R. Pell6n
and colleagues at the Center of Pharmaceutical
Chemistry in Havana, Cuba.19 The radio-
immunoassay kit for cGMP determinations and
14C-labelled t-arginine were obtained from Amer-
sham International. The specific NOS inhibitor t-
Na-monomethyl arginine (t-NMMA) was a kind
of gift from Dr S. Moncada at Wellcome Research
Laboratories. All other chemicals were purchased
from Sigma.
Cytosol preparation: Brains of male Sprague-
Dawley rats weighing 180-200 g were used as the
best source for the conversion of cytosol into
both guanlate cyclase and cNOS. As described
previously," after decapitation rat forebrains were
extracted and washed in ice-cold sucrose buffer
(sucrose 0.32 M, HEPES 10mM, Dt-dithiothreitol
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I mM, pH 7.4), and thereafter homogenized in an
appropriate buffer at pH 7.4 containing Tris-HCl
(50mM), EDTA (0.1mM), EGTA (0.1mM),
dithiothreitol (0.5mM), phenylmethylsulphonyl
fluoride (lmM), pepstatin A (1 btM) and leu-
peptin (2tM). Once extracted, the cytosol
samples were kept at 0-4C for no longer than
15 min before assay of cGMP and -citrulline
production.
Biochemical assays:
cGMP assay. According to previous reports,9
15011 of cytosol were mixed with 501.tl of a
buffer containing Tris (25 mM), MgC12 (5 mM), t-
arginine (100 I.tM), CaC12 (2 mM), 3-isobutyl-1-
methyl xanthine (1 mM), GTP (5mM)and CCA
(1000, 100, 10 or 0btM). Total cGMP level in
each fraction was quantified after 10 min of incu-
bation at 37C by using RIA following the manu-
facturer’s instructions.
[4C]-t-Citrulline assay. As described elsewhere,
2
25 tl of cytosol were mixed with 1001 of an
appropriate buffer at pH 7.4 containing [14C]-t-
arginine, Tris-HCl (50 mM), t-arginine (100 I.tM),
NADPH (100btM), CaC12 (2mM) and CCA (3000,
300, 30, 3 or 0 btM). Final amount of [14C]-citrul-
line generated after 10 min of incubation at 37C
was determined in each fraction by liquid scintil-
liation counting coupled with a set of columns
for ionic exchanging chromatography (Biorack).
Statistical analysis.. All values were expressed as
mean + standard deviation. The number of
experiments (n) is also shown for each case and
was never less than three replicate experiments.
Significant differences between the control group
and the test groups was assessed using Student’s
t-test comparison; p values less than 0.05 or 0.01
were considered significantly different.
Results
After 10 min of cytosol incubation at 37C with
the appropriate buffer, CCA spontaneously inhib-
ited the generation of cGMP (Table 1). This inhi-
bition clearly shows a concentration-dependent
shape in the range between 0.01 and ImM of
CCA. A 100% inhibition of the total amount of
cGMP generated was reached at I mM of CCk
To assess the real amount of cGMP produced in
10 min, in each case the basal cGMP level
(background) was subtracted.
Further results demonstrated that CCA is also
capable of inhibiting, in a concentration-depen-
dent manner, the constitutive generation of t-
citrulline after 10 min of cytosol incubation at
37C with the appropriate buffer (Table 2). This
finding indicates an inhibitory activity in the NOS
metabolic pathway which reaches a maximum of
more than 70% of the inhibition achieved by the
specific antagonist t-NMMA.
It should be noted also that CCA when present
at 3mM scarcely reaches the 70% of the cNOS
Table 1. Inhibitory effect of CCA upon the guanylate cyclase activation pathway
Background +CCA +CCA +CCA +CCA + L-NMMA
(at time 0) (0 mM) (0.01 mM) (0.1 mM) (1 mM) (0.05 mM)
cGMP 2.7 -!- 0.43 12.4 -I- 1.11 7.6 -I- 1.78" 3.4 -t- 0.26* 2.0 ___
0.02* 4.7 -t- 0.80*
(pmol)
Inhibition 50.3 91.7 106.6 78.6
(%)
Replicates n- 6 n 5 n 5 n 3 n 3 n 6
*p< 0.05 and ’p < 0.01 when compared with the production of cGMP in the control group (+CCA 0mM). To assess the real amount of cGMP
generated in 10 min, the level of cGMP present at time zero (background), was for each case subtracted. Percentages of inhibition are calculated by
comparison with the total cGMP generated after 10 min in the absence of CCA. L-NMMA was used as an additional control because of the
involvement of the cNOS metabolic pathway in the generation of cGMP.
Table 2. Inhibitory effect of CCA upon the cNOS activation pathway
+CCA +CCA +CCA +CCA /CCA
(0 mM) (0.003 mM) (0.03 mM) (0.3 mM) (3 mM)
NOS activity 137.7 -I- 3.1 133.0 -I- 2.5 112.5 -I- 1.8" 104.4 -t- 21.2" 38.1 ___
7.4*
(nmol/mg/min)
Inhibition (%) 0 3.4 18.3 24.2 72.3
Replicates n 6 n 4 n 4 n 4 n 3
*p < 0.01 when compared with the control group (+CCA 0 mM).
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inhibition achieved by L-NMMA at 0.05mM,
whereas CCA at lmM exceeds the inhibitory
action of L-NMMA at 0.05mM in cGMP genera-
tion.
Discussion
Considering that the inhibition of the guanylate
cyclase system by CCA proved to be sufficient to
reduce cGMP levels by 50% even at 0.01 mM, this
action will probably have biological significance
in terms of its molecular pharmacodynamics
when in vivo conditions are considered.
Curiously, in our system L-NMMA (0.05mM)
does not abrogate the production of cGMP to
the same extent as is observed for NO genera-
tion. This could be either because there is
another NO-independent mechanism for guany-
late cyclase stimulation
21 or because L-NMMA
(0.05mM) actually fails to affect NO generation,
leaving a low level of cNOS activity. In any case,
the results showing the inhibitory action of CCA
upon the generation of NO are consistent and
could provide an explanation for the inhibition
of cGMP production achieved by CC& However,
for the cNOS system the inhibitory potential of
CCA at 3mM seems to be slightly lower, reaching
70% of the inhibition caused by L-NMMA at
0.05 mM.
Regarding the fact that CCA (1 mM) is able to
inhibit cGMP generation to a greater extent than
is seen by L-NMMA (0.05 mM), and furthermore
CCA (3mM) has a lower inhibitory action than L-
NMMA (0.05mM) upon the generation of NO, it
is possible that in addition to cNOS inhibition,
CCA has another inhibitory effect on the NO-
cGMP metabolic pathway. Such additional inhibi-
tion (25%) has indeed been observed when an
exogenous NO-releasing molecule (SNAP) was
used as a cNOS-independent mechanism for gua-
nylate cyclase stimulation (data not shown). That
could be either due to a NO scavenger activity
(depending on its nitrosable diphenylamine
nitrogen) or to a direct inhibition of the guany-
late cyclase enzyme (by comparison of its struc-
tural similarities with the known guanylate cyclase
inhibitor methylene blue).
It could be important also to elucidate the
mechanism by which CCA inhibits cNOS activity.
The calcium-calmodulin dependence of the
cNOS,
8 the strong calcium chelating properties of
CCA (Dr R. Pell6n, personal communication, and
Reference 19) and the structural resemblance of
CCA with chlorpromazine (a calmodulin antago-
nist that recently has been reported to be an
inhibitor for the activation of brain cNOS and a
suppressor for LPS-induction of iNOS in the
lung22) have given weight to the idea that the
calcium-calmodulin system is the predominant
system involved in such inhibition.
In summary, considering the role of cNOS for
mediating the induction of the iNOS22’23 in addi-
tion to the calacity for high NO levels to cause
tissue damage
24 and to suppress T helper type 1
cells25 (which often work like ’T suppressor
cells’ for antibody production), it is possible to
suggest that most of the therapeutic effects of
CCA are to a great extent due to its capacity to
inhibit the NO-cGMP metabolic pathway, which
is known to play a critical role in arthritis2 and
diabetes,iv Additionally, since most of the cNOS
share their calcium-calmodulin dependence,
28
there are many other potential effects of CCA
that should be investigated in future. In fact,
there are several actions of CCA that potentially
could be explained by such effects. The results
of the present work may indicate a new course
for investigations of the pharmacodynamics of
lobenzarit disodium that may result in the search
for novel strategies for the therapy of chronic
inflammatory auto-immune diseases.
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